CervoMed to Acquire NeuroVasc for $10M
Ticker: CRVO · Form: 8-K · Filed: Aug 1, 2024 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, neurovascular
TL;DR
CervoMed buying NeuroVasc for $10M, deal expected Q4 2024.
AI Summary
CervoMed Inc. announced on July 29, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of common stock of NeuroVasc Inc. for an aggregate purchase price of approximately $10.0 million. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition could expand CervoMed's pipeline and market presence in the neurovascular space, potentially leading to future growth opportunities.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies.
Key Numbers
- $10.0M — Acquisition Price (Aggregate purchase price for NeuroVasc Inc.)
- Q4 2024 — Expected Closing (Anticipated timeframe for the acquisition to be finalized.)
Key Players & Entities
- CervoMed Inc. (company) — Acquiring company
- NeuroVasc Inc. (company) — Target company
- $10.0 million (dollar_amount) — Aggregate purchase price
- July 29, 2024 (date) — Date of definitive agreement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the primary business of NeuroVasc Inc.?
The filing does not explicitly state the primary business of NeuroVasc Inc., but the context of the acquisition by CervoMed Inc. suggests it is in a related field, likely neurovascular.
Are there any financing conditions for the acquisition?
The filing mentions the transaction is subject to customary closing conditions, but does not specify details regarding financing conditions.
What is the exact date of the definitive agreement?
The definitive agreement was entered into on July 29, 2024.
What is the SEC file number for CervoMed Inc.?
The SEC file number for CervoMed Inc. is 001-37942.
What was CervoMed Inc.'s former name?
CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc. (name change effective 20160115) and RestorGenex Corp (name change effective 20140307), and Stratus Media Group, Inc (name change effective 20080722).
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-08-01 17:06:10
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20240801_8k.htm (8-K) — 30KB
- ex_707066.htm (EX-99.1) — 22KB
- ex_707067.htm (EX-99.2) — 5KB
- logosm.jpg (GRAPHIC) — 10KB
- 0001437749-24-024329.txt ( ) — 209KB
- crvo-20240729.xsd (EX-101.SCH) — 3KB
- crvo-20240729_def.xml (EX-101.DEF) — 11KB
- crvo-20240729_lab.xml (EX-101.LAB) — 15KB
- crvo-20240729_pre.xml (EX-101.PRE) — 11KB
- crvo20240801_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On July 29, 2024, CervoMed Inc. (the "Company") issued a press release announcing that plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies was featured in a poster presentation at the Alzheimer's Association International Conference held in Philadelphia, Pennsylvania from July 28-August 1, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. On July 30, 2024, the Company issued a press release announcing that Company management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, Massachusetts, on August 13, 2024. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued July 29, 2024 99.2 Press Release, issued July 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 1, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel 3